EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib (Q24606177)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q28025149)
(Q66809335)
(Q37621431)
(Q114291507)
(Q131377015)
(P304) 434-42
(P407) (Q1860)
(P433) 2
(P478) 7
(P577) +2012-02-00T00:00:00Z
(P921) (Q356033)
(Q418369)
(P1433) (Q2448056)
(P1476) "EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib" (language: en)
(P2093) M Catherine Pietanza
Dana Aftab
Ronglai Shen
Zhiguo Zhao
Katherine Hutchinson
Thomas Stout
Vincent Miller
Naiyer Rizvi
(P2860) (Q24649549)
(Q24646295)
(Q24794765)
(Q24561953)
(Q27658766)
(Q27824829)
(Q27824812)
(Q27851633)
(Q27851406)
(Q27860881)
(Q27860758)
(Q27861059)
(Q27861098)
(Q27860904)
(Q29547545)
(Q36406541)
(Q34762839)
(Q34760642)
(Q34694358)
(Q34773458)
(Q33810574)
(Q39843658)
(Q37000611)
(Q34638493)
(Q33906140)
(Q33821320)
(Q42725846)
(Q43061055)
(Q46643606)
(P4510) (Q112236343)
other details
description scientific article

External Links